Aderans Research Acquires Intercytex Assets
(Atlanta, GA, March 24, 2010) Aderans Research Institute Inc. (ARI) announced it purchased key
technology assets from Regenerative Medicine Assets Limited (formerly Intercytex Group plc), a
leading UK hair regeneration company.
Atlanta, GA (PRWeb UK) March 25, 2010 -- Aderans Research Institute Inc. (ARI) announced it purchased key
technology assets from Regenerative Medicine Assets Limited (formerly Intercytex Group plc), a leading UK hair
regeneration company. The acquisition represents a significant consolidation within the hair regeneration
industry, as ARI is absorbing the scientific assets of a company that was its leading competitor.
“This acquisition is a major step forward for ARI,” said Vern Liebmann, Vice President, Operations. “Through
this deal, we’ve been able to consolidate the majority of key patents and know-how in the hair regeneration field,
an achievement that can accelerate our ability to deliver a commercially viable product to market. This acquisition
was only possible thanks to the considerable financial support of Aderans Holdings Company, Ltd., of Japan.”
The purchase includes assets related to the ICX-TRC product that Regenerative Medicine Assets Limited had
been developing. ICX-TRC is an autologous hair regeneration therapy for the treatment of male pattern baldness
and female diffuse alopecia.
The deal comes as ARI is expanding its Phase 2 clinical study of cell-based hair regeneration, in which it recently
treated the trial’s 100th subject. “We’ve acquired important proprietary knowledge that includes Intercytex’s
clinical efforts to date,” noted Ken Washenik, MD PhD, Executive Vice President. “This information should
substantially augment our ongoing efforts to produce a cell-based treatment for hair loss.”
“Cellular regeneration represents the leading edge of research into hair loss,” said Kurt Stenn, MD, Vice
President and Chief Scientific Officer. “Combining the knowledge stores of two of the leading companies in this